Drug Profile
ST 101
Alternative Names: ST101; ZSET-1446Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Zenyaku Kogyo
- Developer Sonexa Therapeutics
- Class Antidementias; Indans; Nootropics; Small molecules; Spiro compounds
- Mechanism of Action Acetylcholine stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Essential tremor
Most Recent Events
- 22 Jul 2015 Discontinued - Phase-II for Alzheimer's disease in USA and Canada (PO)
- 22 Jul 2015 Discontinued - Phase-II for Essential tremor in USA (PO)
- 06 May 2011 Phase-II clinical trials in Essential tremor in USA (PO)